{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Investigational
Source:
NCT03398655: Phase 3 Interventional Completed Recurrent Platinum Resistant Ovarian Cancer
(2017)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT04353518: Phase 3 Interventional Unknown status COVID-19
(2020)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT04281485: Phase 3 Interventional Active, not recruiting Duchenne Muscular Dystrophy
(2020)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT02282215: Phase 2 Interventional Completed Acute Myeloid Leukemia
(2014)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
INN:peboctocogene camaparvovec [INN]
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT04376034: Phase 3 Interventional Recruiting COVID19
(2020)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
INN:zamtocabtagene autoleucel [INN]
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT02439450: Phase 1/Phase 2 Interventional Completed Non-small Cell Lung Cancer
(2015)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT00423124: Phase 1/Phase 2 Interventional Completed Hematological Malignancies
(2002)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT03780049: Phase 3 Interventional Unknown status Hepatocellular Carcinoma
(2018)
Source URL:
Class:
STRUCTURALLY DIVERSE